Back to Search
Start Over
Bevacizumab in Oncology: Boon or Bane.
- Source :
-
Indian Journal of Medical & Paediatric Oncology . Aug2022, Vol. 43 Issue 4, p390-391. 2p. - Publication Year :
- 2022
-
Abstract
- For the remaining treatment applications of bevacizumab: metastatic breast cancer, renal cell carcinoma, and glioblastoma multiforme, various clinical trials have failed to show a significant benefit in overall survival. Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factors (VEGF). It is approved for a range of solid cancers such as ovarian cancer, colorectal cancer, glioblastoma multiforme, advanced non-squamous non-small cell lung cancer (NSCLC), cervical cancer, renal cell carcinoma, and metastatic breast cancer. [Extracted from the article]
- Subjects :
- *BEVACIZUMAB
*VASCULAR endothelial growth factors
Subjects
Details
- Language :
- English
- ISSN :
- 09715851
- Volume :
- 43
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Indian Journal of Medical & Paediatric Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 158872739
- Full Text :
- https://doi.org/10.1055/s-0042-1746422